Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

Abu Dhabi successfully completes its first gene therapy for genetic blood disorders, revolutionizing treatment approaches for ...

At the height of the COVID-19 pandemic in 2020, Marvin Collins ’22, a bioengineering student, was balancing their Stanford classes from home in Alabama while also helping bioengineering professor ...

CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...

Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting ...